Companies · TXG
10x Genomics
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 7, 2026
10x Genomics Q2 2026: Consumables strength masks 47% instrument collapse and $25.8M license revenue cliff from non-recurring 2025 settlements
10x Genomics posted total revenue of $151.0 million for Q2 2026 versus $172.9 million in Q2 2025, with the decline driven entirely by the absence of $27.3 million in one-time Bruker litigation settlement revenue that inflated the prior-year period. Products and services revenue — the operationally meaningful baseline — grew 3% year-over-year to $149.1 million, powered by consumables expanding 7% to $130.8 million while instrument revenue collapsed 47% to $7.7 million, signaling acute capex restraint among customers. Gross margin on products and services reached 74% in Q2 2026, a 200-basis-point improvement over Q2 2025, driven by $2.6 million in tariff refunds, lower inventory write-downs, and reduced warranty costs — structural cost discipline that partially offsets the instrument demand deterioration.
Tone: mixedRevenue
$642.8M
TXG 10-K · FY 2025
Employees
1,178
Revenue growth YoY
+5%
Founded
2012
Profile
TXG 10-K Item 1 · Feb 13, 202610x Genomics is a life sciences technology company that develops instruments, consumables and software enabling researchers to analyze biological systems at single-cell and spatial resolution. Its two product portfolios — Single Cell (Chromium platform) and Spatial (Visium and Xenium platforms) — serve academic, government and biopharmaceutical customers in over 50 countries. The company has sold 8,046 cumulative instruments since its first product launch in mid-2015.
Read filing description ↓ Collapse description ↑
Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience. Since launching our first product in mid-2015 through December 31, 2025, we have sold 8,046 instruments to researchers around the world, including academic and translational researchers and biopharmaceutical companies. Our commercial product portfolio is made up of our Single Cell and Spatial solutions. Our products include our instruments, which include our Chromium instruments, our Visium CytAssist and our Xenium Analyzer, and our consumables, which include proprietary microfluidic chips, slides, reagents and other consumables for our Single Cell and Spatial solutions. We bundle our software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. Customers purchase instruments and consumables from us for use in their experiments. We also derive revenue from post-warranty service contracts for our instruments.
Primary products
- Chromium X Series
- Chromium instruments
- Visium CytAssist
- Xenium Analyzer
- QuantumScale Single Cell RNA kits
- Single Cell Methylation kits
Business segments
End markets
Geographies
Named competitors
“We believe we are differentiated from our competitors for many reasons, including the capabilities and performance of our products, our advanced proprietary technologies protected by substantial intellectual property, our rigorous product development processes and scalable infrastructure and our superior customer experience and multidisciplinary teams.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenue increased 5% year-over-year to $642.8 million in 2025, driven primarily by $46.1 million in license and royalty revenue (versus $0.3 million in 2024), partially offset by a modest decline in products and services revenue.
The rest of TXG is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.